RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis

Signaling via the receptor of advanced glycation end products (RAGE)—though complex and not fully elucidated in the setting of diabetes—is considered a key injurious pathway in the development of diabetic nephropathy (DN). We report here that RAGE deletion resulted in increased expression of fibrotic markers (collagen I and IV, fibronectin) and the inflammatory marker MCP-1 in primary mouse mesangial cells (MCs) and in kidney cortex. RNA sequencing analysis in MCs from RAGE−/− and wild-type mice confirmed these observations. Nevertheless, despite these gene expression changes, decreased responsiveness to transforming growth factor-β was identified in RAGE−/− mice. Furthermore, RAGE deletion conferred a more proliferative phenotype in MCs and reduced susceptibility to staurosporine-induced apoptosis. RAGE restoration experiments in RAGE−/− MCs largely reversed these gene expression changes, resulting in reduced expression of fibrotic and inflammatory markers. This study highlights that protection against DN in RAGE knockout mice is likely to be due in part to the decreased responsiveness to growth factor stimulation and an antiapoptotic phenotype in MCs. Furthermore, it extends our understanding of the role of RAGE in the progression of DN, as RAGE seems to play a key role in modulating the sensitivity of the kidney to injurious stimuli such as prosclerotic cytokines.

[1]  E. Brennan,et al.  Study of microRNA in diabetic nephropathy: Isolation, quantification and biological function , 2015, Nephrology.

[2]  M. Torres-Ramos,et al.  Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress. , 2014, CNS & neurological disorders drug targets.

[3]  O. P. Kalra,et al.  Role of advanced glycation end products ( AGEs ) – induced receptor ( RAGE ) expression in diabetic vascular complications , 2014 .

[4]  M. Remáková,et al.  The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis. , 2014, Rheumatology.

[5]  K. Sourris,et al.  Deletion of bone-marrow-derived receptor for AGEs (RAGE) improves renal function in an experimental mouse model of diabetes , 2014, Diabetologia.

[6]  F. Ashcroft,et al.  Deletion of Nicotinamide Nucleotide Transhydrogenase: A New Quantitive Trait Locus Accounting for Glucose Intolerance in C57BL/6J Mice. Diabetes 2006;55:2153–2156 , 2014, Diabetes.

[7]  A. Simm,et al.  Role of advanced glycation end products in cellular signaling , 2014, Redox biology.

[8]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[9]  S. Phipps,et al.  RAGE and TLRs: relatives, friends or neighbours? , 2013, Molecular immunology.

[10]  B. Zhivotovsky,et al.  S100A4 interacts with p53 in the nucleus and promotes p53 degradation , 2013, Oncogene.

[11]  Jianling Xie,et al.  Cellular signalling of the receptor for advanced glycation end products (RAGE). , 2013, Cellular signalling.

[12]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[13]  Merlin C. Thomas,et al.  Alagebrium Reduces Glomerular Fibrogenesis and Inflammation Beyond Preventing RAGE Activation in Diabetic Apolipoprotein E Knockout Mice , 2012, Diabetes.

[14]  A. Schmidt,et al.  Signal transduction in receptor for advanced glycation end products (RAGE). SOLUTION STRUCTURE OF C-TERMINAL RAGE (ctRAGE) AND ITS BINDING TO mDia1. , 2012, Journal of Biological Chemistry.

[15]  A. Schmidt,et al.  Signal Transduction in Receptor for Advanced Glycation End Products (RAGE) , 2011, The Journal of Biological Chemistry.

[16]  S. Mishra,et al.  S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence , 2011, Cancer and Metastasis Reviews.

[17]  Merlin C. Thomas,et al.  Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. , 2010, American journal of physiology. Renal physiology.

[18]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[19]  S. Yamagishi,et al.  Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. , 2010, Pharmacological research.

[20]  M. Cooper,et al.  RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. , 2009, Journal of the American Society of Nephrology : JASN.

[21]  R. Ramasamy,et al.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease , 2009, Expert Reviews in Molecular Medicine.

[22]  Merlin C. Thomas,et al.  Receptor for Advanced Glycation End Products (RAGE) Deficiency Attenuates the Development of Atherosclerosis in Diabetes , 2008, Diabetes.

[23]  N. Kaminski,et al.  A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. , 2008, The American journal of pathology.

[24]  C. Doglioni,et al.  Maturing Dendritic Cells Depend on RAGE for In Vivo Homing to Lymph Nodes1 , 2008, The Journal of Immunology.

[25]  M. Cooper,et al.  Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product–Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C-α–Dependent Pathway , 2008, Diabetes.

[26]  K. Herold,et al.  Receptor for advanced glycation end products expression on T cells contributes to antigen-specific cellular expansion in vivo. , 2007, Journal of immunology.

[27]  K. Herold,et al.  Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. , 2007, Current molecular medicine.

[28]  M. Rastaldi,et al.  Apoptosis in the kidneys of patients with type II diabetic nephropathy. , 2007, Kidney international.

[29]  L. Audoly,et al.  Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[30]  M. Cooper,et al.  Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? , 2007, Endocrinology.

[31]  Masayoshi Takeuchi,et al.  RAGE Control of Diabetic Nephropathy in a Mouse Model , 2006, Diabetes.

[32]  Y. Tomino,et al.  Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  T. Imaizumi,et al.  Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. , 2005, Microvascular research.

[34]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Stern,et al.  Understanding RAGE, the receptor for advanced glycation end products , 2005, Journal of Molecular Medicine.

[36]  U. Andersson,et al.  RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages , 2005, Scandinavian journal of immunology.

[37]  T. Kern,et al.  High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. , 2005, Kidney international.

[38]  R. Bucala,et al.  AGEs activate mesangial TGF-b –Smad signaling via an angiotensin II type I receptor interaction , 2010 .

[39]  Merlin C. Thomas,et al.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.

[40]  E. Schleicher,et al.  Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. , 2004, The Journal of clinical investigation.

[41]  E. Bottinger,et al.  Utility of endogenous creatinine clearance as a measure of renal function in mice. , 2004, Kidney international.

[42]  L. Truong,et al.  Advanced glycation end products activate Smad signaling via TGF‐β‐dependent and ‐independent mechanisms: implications for diabetic renal and vascular disease , 2004 .

[43]  L. Denner,et al.  Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. , 2004, Diabetes.

[44]  L. Truong,et al.  Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  G. Jerums,et al.  The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  V. D’Agati,et al.  RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.

[47]  S. Takasawa,et al.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. , 2003, The Biochemical journal.

[48]  S. Menini,et al.  Glomerular Cell Replication and Cell Loss through Apoptosis in Experimental Diabetes mellitus , 2002, Nephron.

[49]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[50]  Hyung-Ryong Kim,et al.  Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. , 2000, Pharmacological research.

[51]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.

[52]  B. Brüne,et al.  Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7receptors. , 1998, American journal of physiology. Renal physiology.

[53]  B. Brüne,et al.  Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. , 1998, The American journal of physiology.

[54]  G. Becker,et al.  Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring. , 1998, Journal of the American Society of Nephrology : JASN.

[55]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[56]  W. Cefalu,et al.  Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. , 1994, Clinical chemistry.

[57]  M. Grigorian,et al.  Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. , 1989, Genes & development.